|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008059,
umls-concept:C0011015,
umls-concept:C0020789,
umls-concept:C0023452,
umls-concept:C0031809,
umls-concept:C0035020,
umls-concept:C0376152,
umls-concept:C0439611,
umls-concept:C0600688,
umls-concept:C0680730,
umls-concept:C0684224,
umls-concept:C0752079,
umls-concept:C1148554,
umls-concept:C1257890,
umls-concept:C1521750,
umls-concept:C1707455,
umls-concept:C2603343,
umls-concept:C2728259
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-3-5
|
|
pubmed:abstractText |
An escalating-dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L-asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75%) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59%) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0098-1532
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
124-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1734217-Adolescent,
pubmed-meshheading:1734217-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1734217-Asparaginase,
pubmed-meshheading:1734217-Bone Marrow,
pubmed-meshheading:1734217-Child,
pubmed-meshheading:1734217-Child, Preschool,
pubmed-meshheading:1734217-Daunorubicin,
pubmed-meshheading:1734217-Drug Administration Schedule,
pubmed-meshheading:1734217-Female,
pubmed-meshheading:1734217-Hematopoiesis,
pubmed-meshheading:1734217-Humans,
pubmed-meshheading:1734217-Idarubicin,
pubmed-meshheading:1734217-Infant,
pubmed-meshheading:1734217-Male,
pubmed-meshheading:1734217-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1734217-Prednisone,
pubmed-meshheading:1734217-Remission Induction,
pubmed-meshheading:1734217-Vincristine
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
|
|
pubmed:affiliation |
University of California School of Medicine, Los Angeles.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Controlled Clinical Trial
|
